Adverse events: Any prolactin‐related ‐ medium term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any prolactin‐related ‐ medium term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).
1 finding from 1 review
Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event · patients with schizophrenia
1 finding from 1 review
Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes global state: Relapse (any reason) ‐ long term Number of… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Specific behaviour: aggression ‐ important decrease in aggression · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviour: aggression ‐ important decrease in aggression compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Repeated need for rapid tranquillisation · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviours ‐ threat or injury to others/self compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Adverse effects ‐ any serious, specific adverse effects · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcomes ‐ overall improvement · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower global outcomes ‐ overall improvement compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Leaving the study early · people with long‐term aggression in psychosis
HALOPERIDOL showed no clear difference in leaving the study early compared with OTHER ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Economic outcomes · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects dystonia ‐ short term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review